The Good, the Bad, the Ugly: De-Risk Immunogenicity and Immunotoxicity

In this webinar, we explore the challenges of assessing the immunosafety profile when moving a drug candidate to first-in-human studies. Our expert shares key considerations and pitfalls to avoid along the way. Case studies highlight how in vitro immunotoxicity assessments add significant value by predicting risk early. This knowledge allows for modifications to the candidate or package design to mitigate risk and increase the likelihood of a successful study.